Achieving durable viral suppression in children and adolescents requires earlier diagnosis, optimized child-friendly regimens, routine resistance testing, and integrated management of comorbidities. Key priorities include pediatric evaluation of long-acting and novel agents, development of improved immunologic and virologic markers, and scalable approaches to strengthen engagement in care and reduce global inequities.
Borjesson et al. (Wed,) studied this question.